



02 July 2026

ASX Announcement

Singapore patent grant strengthens ISLA-101 intellectual property portfolio

- Singapore patent granted covering use of ISLA-101 to treat flavivirus, including Dengue, and Chikungunya virus infections
- Patent protects use of ISLA-101 as a standalone antiviral therapy, further strengthening the Company's intellectual property estate
- Broadens ISLA-101 intellectual property protection beyond Dengue to include Chikungunya virus infection
- Like Dengue, Chikungunya is a mosquito-borne viral disease with significant global health impact and no widely available antiviral treatment.
- Patent remains in force until 16 April 2034, supporting long-term commercial exclusivity
- Singapore is an important market within the Asia-Pacific region, where Dengue and other mosquito-borne viral diseases remain endemic
- Grant further reinforces Island's commercial and partnering position as it advances ISLA-101 for Dengue and other flavivirus indications

MELBOURNE Australia, 02 July 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise that the Intellectual Property Office of Singapore has granted a patent protecting the use of ISLA-101 for the treatment of flavivirus and Chikungunya virus infections.

The patent, entitled "Method of Viral Inhibition" (Singapore Patent No. 10202011533P), includes claims directed to the use of ISLA-101, in the absence of another antiviral agent, for the treatment of flavivirus infections, including Dengue, and Chikungunya virus infection. Similar to Dengue, Chikungunya is a mosquito-borne viral disease with significant global health impact and no widely available antiviral treatment.

The patent is owned by Monash University and forms part of Island's exclusively licensed intellectual property portfolio supporting the development and commercialisation of ISLA-101. The patent provides protection until 16 April 2034.

The grant further strengthens Island's intellectual property portfolio for ISLA-101, enhancing the Company's long-term commercial position as it advances the program through clinical development and expands opportunities for future partnering and commercialisation.

Singapore represents a strategically important jurisdiction within the Asia-Pacific region, where Dengue and other mosquito-borne viral diseases continue to present a significant public health burden. Protection in this market complements Island's broader intellectual property strategy to secure commercial exclusivity across key territories with high disease prevalence and commercial relevance.



Island continues to actively build and protect its intellectual property portfolio as a core component of its strategy to maximise the long-term value of ISLA-101 across multiple viral disease indications.

Management Commentary:

Chief Executive Officer and Managing Director, Dr David Foster, said: *"The grant of this Singapore patent further strengthens the IP supporting ISLA-101 and expands protection in a strategically important region where Dengue and other flavivirus infections remain a significant health challenge.*

"As we continue advancing ISLA-101 through clinical development, maintaining and expanding our patent portfolio remains an important component of our strategy to maximise the long-term commercial value of the program. This patent further enhances the exclusivity surrounding ISLA-101 and supports future partnering and commercial opportunities across Asia."

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of Dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.